About
Biological Anti-Angiogenesis Tumor Therapeutics, Pharmaceuticals
Biological CM101 interacts with HP59 (See Wikipedia) on tumor capillary endothelium, induces complement activation and an acute inflammatory response in the tumor vasculature and surrounding tumor. Tumorend is conducting clinical trials and developing CM101 as an anti-solid tumor agent.
Contact
Reviews (0)
Write a Review
Detailed Information
- Location TypeHQ
- Opening Date2008
- Annual Revenue Estimate$100,001 to $500,000
- SIC Code show
- Employees2 to 4
- Contactsshow
- COO Armand C Alciatore
- Phone 5043901700
- Email [email protected]
- Fax 2252081148
Is this your listing?
Tumorend, LLC is an unclaimed page. Claim it for free to:
Update listing information
Respond to reviews
Add business hours, photos and much more